Myriad Genetics Inc (NASDAQ: MYGN)

Myriad Genetics is a leading molecular diagnostics and precision medicine company that develops and commercializes molecular tests to help patients and providers uncover genetic insights. The company’s tests assess disease risk, guide treatment decisions, and support earlier detection across medical specialties such as oncology, women’s health, and mental health. By integrating genetic and genomic data, Myriad aims to improve patient care, enable precise treatment, and lower healthcare costs.

Myriad generates revenue primarily through the sale of its diagnostic tests to healthcare providers, laboratories, and patients. Revenue is derived from a diverse portfolio including hereditary cancer tests, tumor profiling assays, prenatal screening products, and pharmacogenomic tests. The company serves customers in the United States and internationally through direct sales forces, partnerships, and distribution channels, with a focus on community medicine and integrated healthcare systems.

The company operates through the following segments:

• Oncology: This segment focuses on cancer risk assessment, treatment selection, and monitoring through genetic and genomic tests. Key products include MyRisk for hereditary cancer risk, BRACAnalysis CDx and MyChoice CDx as companion diagnostics for PARP inhibitor therapy, Prolaris for prostate cancer prognosis, EndoPredict for breast cancer prognosis, and Precise Tumor for comprehensive genomic profiling. The segment also includes Precise MRD for minimal residual disease detection and is expanding through collaborations such as the partnership with PATHOMIQ for AI-driven prostate cancer diagnostics and SOPHiA GENETICS for liquid biopsy companion diagnostics.

• Women’s Health: This segment provides genetic insights and prenatal solutions for reproductive health and cancer risk assessment. Core products include Prequel for non-invasive prenatal screening, Foresight for expanded carrier screening, SneakPeek for early fetal gender detection, and FirstGene as a multi-modal prenatal risk assessment. The segment leverages technologies such as AMPLIFY to improve test performance across diverse populations and supports early intervention for chromosomal disorders and inherited conditions.

• Mental Health: This segment uses pharmacogenomics to guide psychotropic medication selection for conditions such as depression, anxiety, and ADHD. The primary offering is the GeneSight test, which analyzes patient genes to inform treatment decisions and reduce adverse drug reactions. GeneSight covers over 60 psychiatric medications and is supported by clinical studies showing improved patient outcomes when used to guide therapy.

Myriad holds a leading position in the molecular diagnostics industry, particularly in hereditary cancer testing where it is a pioneer and trusted provider across eleven cancer types. The company faces competition from firms such as Natera, Foundation Medicine, Tempus, Guardant Health, Quest Diagnostics, and Laboratory Corporation of America in oncology; Natera, BillionToOne, and Fulgent Genetics in women’s health; and Genomind and Tempus in mental health. Its competitive advantages include a broad test menu, strong clinical validity, extensive commercial reach, and strategic partnerships that enhance innovation and market access.

Myriad serves a diverse customer base including oncologists, obstetricians, gynecologists, primary care physicians, psychiatrists, hospitals, clinics, and laboratory networks. The company also partners with biopharma firms for biomarker identification and companion diagnostic development. Patients benefit from testing through improved risk assessment and personalized treatment guidance across oncology, prenatal, and mental health care settings.

Myriad has invested in innovation through sustained research and development, with a focus on expanding its oncology portfolio and enhancing prenatal and mental health offerings. The company maintains a strong intellectual property portfolio, with patents covering key technologies such as Precise MRD expected to last until 2037. Operational improvements, including the transition to next-generation laboratory facilities, support scalability and cost efficiency. These efforts reinforce Myriad’s strategy to drive profitable growth through differentiated diagnostics and integrated precision medicine solutions.